The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms

Journal of Clinical Psychiatry

Volumn 60, Issue 10, 1999, Pages 649-657

  Miller, Alexander L ^a   Chiles, John A ^b   Chiles, Judith K ^b   Crismon, M Lynn ^b   Rush, A John ^b   Shon, Steven P ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TIOTIXENE; TRAZODONE; VENLAFAXINE; ZOLPIDEM TARTRATE;

AKATHISIA; ALGORITHM; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0032717195     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1002     Document Type: Article

References (55)

1. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351
2. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:284-291
3. Expert Consensus Guideline Series: Treatment of Schizophrenia. J Clin Psychiatry 1996;57(suppl 12B):1-58
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63
5. Lehman AF, Steinwachs DM, and the Co-investigators of the PORT Project. Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
6. Carpenter WT. The risk of medication-free research. Schizophr Bull 1997;23:11-18
7. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull 1997;23:3-9
8. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-523
9. McCarthy RH, Terkelson KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995;28:61-63
10. Mowerman S, Siris S. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197
11. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397
12. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine; a double-blind, placebo-controlled study. Br J Psychiatry 1997;171:559-573
13. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone? [letter] Am J Psychiatry 1996;153:843
14. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
15. Marder SR. Risperidone: clinical development: North American results. Clin Neuropharmacol 1992;15:92A-93A
16. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254
17. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
18. Arvanitis LA, Miller BG. Seroquel Trial 13 Study Group: multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
19. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
20. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/ benztropine. Arch Gen Psychiatry 1988;45:789-796
21. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139
22. Kane JM. Critical drug appraisal: clozapine. Drug Ther 1991;21:35-40
23. Brecher M, Kane JM, Okamoto A, et al. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year [poster]. Presented at the 151st Annual Meeting of the American Psychiatric Association; May 30-June 4, 1998; Toronto, Ontario, Canada
24. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
25. Conley RR, Brecher M, and the Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizo-affective disorder. Presented at the 11th European Collegium Neuro-Psychopharmacologicum Congress; Oct 31, 1998; Paris, France
26. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]. Arch Gen Psychiatry 1989;46:672
27. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report. Psychopharmacology (Berl) 1989;99(suppl):S68-S72
28. Shore D, Matthews S, Cott J, et al. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21: 333-338
29. Shiovitz TM, Welke TL, Tigel PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595
30. Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-1384
31. Gupta S, Daniel DG. Cautions in the clozapine-to-risperidone switch [letter]. Ann Clin Psychiatry 1995;7:149
32. Parsa MA, Al-Lahham YH, Ramirez JR, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 1993;13: 154-155
33. Kane JM, Woerner M, Lieberman JA. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;8:52-56
34. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
35. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(suppl 3):3-7
36. Safferman AZ, Munne R. Combining clozapine with ECT. Convuls Ther 1992;8:141-143
37. Klapheke MM. Clozapine, ECT and schizoaffective disorder, bipolar type. Convuls Ther 1991;7:36-39
38. Landy DA. Combined use of clozapine and electroconvulsive therapy. Convuls Ther 1991;7:218-221
39. Kales H, Tandon R, DeQuardo JR, et al. Combined electroconvulsive therapy and clozapine in schizophrenia [abstract]. Biol Psychiatry 1995; 37:678
40. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160 (suppl 17):54-59
41. Lieberman JA. Pharmacotherapy for patients with first-episode, acute, and refractory schizophrenia. Psychiatr Ann 1996;26:515-518
42. Luchins DJ, Klass D, Hanrahan P, et al. Alteration in the recommended dosing schedule for risperidone. Am J Psychiatry 1998;155:365-366
43. Sheitman BB, Lindgren JC, Early J, et al. High-dose olanzapine for treatment-refractory schizophrenia [letter]. Am J Psychiatry 1997;154:1626
44. Liddle PF, Barnes TRE, Morris D, et al. Three syndromes in chronic schizophrenia. Br J Psychiatry 1989;155(suppl 7):119-122
45. Mahurin RK, Velligan DI, Miller AL. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res 1998;79:139-149
46. Buchanan RW, Kirkpatrick B, Heinrichs DW, et al. Clinical correlates of the deficit syndrome in schizophrenia. Am J Psychiatry 1990;147:290-294
47. Carpenter WT, Heinrich PW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583
48. Eaton WW, Thar R, Federman B, et al. Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 1995;52: 127-134
49. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330
50. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
51. Alphs LD, Summerfelt A, Lann H, et al. The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989;25:159-163
52. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982;39:784-788
53. Eckert SL, Diamond PM, Miller AL, et al. A comparison of instrument sensitivity to negative symptom change. Psychiatry Res 1996;63:67-75
54. Lieberman JA, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-376
55. Siris SG. Diagnosis of secondary depression in schizophrenia. Schizophr Bull 1991;17:75-98